Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2.
DCIS
HER2
recurrence
tumour immune microenvironment
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
03 May 2022
03 May 2022
Historique:
received:
22
03
2022
revised:
25
04
2022
accepted:
30
04
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
Increasing evidence suggests that the significance of the tumour immune microenvironment (TIME) for disease prognostication in invasive breast carcinoma is subtype-specific but equivalent studies in ductal carcinoma in situ (DCIS) are limited. The purpose of this paper is to review the existing data on immune cell composition in DCIS in relation to the clinicopathological features and molecular subtype of the lesion. We discuss the value of infiltration by various types of immune cells and the PD-1/PD-L1 axis as potential markers of the risk of recurrence. Analysis of the literature available in PubMed and Medline databases overwhelmingly supports an association between densities of infiltrating immune cells, traits of immune exhaustion, the foci of microinvasion, and overexpression of HER2. Moreover, in several studies, the density of immune infiltration was found to be predictive of local recurrence as either in situ or invasive cancer in HER2-positive or ER-negative DCIS. In light of the recently reported first randomized DCIS trial, relating recurrence risk with overexpression of HER2, we also include a closing paragraph compiling the latest mechanistic data on a functional link between HER2 and the density/composition of TIME in relation to its potential value in the prognostication of the risk of recurrence.
Identifiants
pubmed: 35625798
pii: biomedicines10051061
doi: 10.3390/biomedicines10051061
pmc: PMC9138378
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : National Science Center
ID : 2018/29/N/NZ3/02407
Références
BMC Cancer. 2015 Jun 11;15:468
pubmed: 26062614
Histopathology. 2020 May;76(6):852-864
pubmed: 31883279
Breast Cancer Res Treat. 2016 Oct;159(3):553-63
pubmed: 27624164
Biomedicines. 2022 Jan 24;10(2):
pubmed: 35203458
Breast Cancer Res. 2020 Mar 26;22(1):32
pubmed: 32216826
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Ann Surg Oncol. 2017 Oct;24(10):2999-3003
pubmed: 28766212
Cancer Med. 2016 Jul;5(7):1607-18
pubmed: 27061242
Oncoimmunology. 2016 Aug 18;5(10):e1218106
pubmed: 27853639
Cancer Res. 2018 Apr 15;78(8):2040-2051
pubmed: 29382706
J Biomed Sci. 2019 Oct 20;26(1):78
pubmed: 31629410
Clin Cancer Res. 2021 Oct 1;27(19):5317-5324
pubmed: 34380636
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Nature. 2006 May 11;441(7090):235-8
pubmed: 16648838
Mol Clin Oncol. 2020 Jul;13(1):67-72
pubmed: 32454975
Clin Cancer Res. 2017 Sep 1;23(17):5210-5217
pubmed: 28611201
Neoplasia. 2020 Nov;22(11):576-589
pubmed: 32980776
Cancer Res. 2016 Jan 15;76(2):227-38
pubmed: 26637667
BMC Cancer. 2018 Feb 3;18(1):129
pubmed: 29394917
Cancer Res. 2014 Nov 1;74(21):5942-7
pubmed: 25320004
Clin Breast Cancer. 2018 Apr;18(2):157-167.e6
pubmed: 29325859
Biomed Res Int. 2015;2015:521957
pubmed: 26583116
J Clin Pathol. 2016 Oct;69(10):890-8
pubmed: 27030304
JCI Insight. 2019 Oct 3;4(19):
pubmed: 31465302
J Immunother Cancer. 2019 Feb 6;7(1):34
pubmed: 30728081
Mod Pathol. 2019 Oct;32(10):1460-1472
pubmed: 31175327
Clin Med Oncol. 2008;2:7-18
pubmed: 21892261
Cancers (Basel). 2020 Mar 10;12(3):
pubmed: 32164163
Cancers (Basel). 2020 Apr 26;12(5):
pubmed: 32357420
J Surg Res. 2007 Jun 1;140(1):109-14
pubmed: 17291532
Oncoimmunology. 2015 Apr 1;4(10):e1022301
pubmed: 26451293
Breast Cancer Res Treat. 2014 Jul;146(1):15-24
pubmed: 24842267
Br J Cancer. 2020 May;122(10):1496-1506
pubmed: 32203210
Histopathology. 2019 Jun;74(7):1025-1035
pubmed: 30725481
Clin Cancer Res. 2004 Dec 15;10(24):8152-62
pubmed: 15623589
Lancet Oncol. 2017 Dec;18(12):e731-e741
pubmed: 29208439
Transl Oncol. 2019 Feb;12(2):245-255
pubmed: 30439625
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
J Cancer. 2017 Nov 1;8(19):4098-4105
pubmed: 29187886
J Invest Dermatol. 2006 Jan;126(1):15-24
pubmed: 16417213
Mod Pathol. 2018 Aug;31(8):1226-1236
pubmed: 29559742
Breast Cancer Res Treat. 2019 Aug;177(1):17-27
pubmed: 31134489
Clin Cancer Res. 2021 May 15;27(10):2861-2867
pubmed: 33727261
Cancer Immunol Res. 2018 Jun;6(6):658-670
pubmed: 29622580
Nat Commun. 2018 Jan 2;9(1):21
pubmed: 29295986
Cancer Res. 2007 Mar 1;67(5):1883-6
pubmed: 17332313
Virchows Arch. 2021 Apr;478(4):679-686
pubmed: 33140128
Cancer Discov. 2017 Oct;7(10):1098-1115
pubmed: 28652380
Hum Pathol. 2018 Dec;82:158-162
pubmed: 30067949
Mod Pathol. 2018 Dec;31(12):1807-1815
pubmed: 29955142
Oncotarget. 2017 Jul 12;8(38):63901-63910
pubmed: 28969039
Immunology. 2010 Apr;129(4):474-81
pubmed: 20201977
Brief Funct Genomics. 2019 Mar 22;18(2):99-106
pubmed: 29554204
Oncoimmunology. 2018 Sep 21;8(1):e1512942
pubmed: 30546951
Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1386-9
pubmed: 19383888
Lab Invest. 2022 Apr;102(4):376-390
pubmed: 34775491
Breast Cancer Res Treat. 2021 Jan;185(2):261-279
pubmed: 33011829
Cancer Cell. 2007 Nov;12(5):409-11
pubmed: 17996643
Cancer Res. 2015 Sep 15;75(18):3980-90
pubmed: 26249178
Mol Cancer. 2019 Nov 20;18(1):165
pubmed: 31747941
Mod Pathol. 2020 Sep;33(9):1773-1782
pubmed: 32341499
Development. 2000 Jun;127(11):2269-82
pubmed: 10804170
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Hum Pathol. 2016 Jan;47(1):78-84
pubmed: 26541326
Mod Pathol. 2002 Dec;15(12):1318-25
pubmed: 12481013
Mol Cancer Res. 2021 Apr;19(4):623-635
pubmed: 33443130
Br J Cancer. 2003 Nov 17;89(10):1920-6
pubmed: 14612904
Cell Mol Life Sci. 2018 Feb;75(4):689-713
pubmed: 29032503
J Pathol. 2005 Jan;205(2):248-54
pubmed: 15641021
Nat Commun. 2021 May 20;12(1):2965
pubmed: 34017005
Cancer Cell. 2007 Nov;12(5):479-91
pubmed: 17996651
Cancer Immunol Res. 2020 Apr;8(4):422-427
pubmed: 32238387
Cancer Res. 2011 Sep 1;71(17):5601-5
pubmed: 21846822
Breast Cancer Res Treat. 2017 Jan;161(1):17-28
pubmed: 27785654
Virchows Arch. 2020 Jun;476(6):825-833
pubmed: 31897820
Ann Oncol. 2017 Feb 1;28(2):321-328
pubmed: 28426105
Ann Surg Oncol. 2019 Oct;26(10):3337-3343
pubmed: 31240590
Mod Pathol. 2016 Mar;29(3):249-58
pubmed: 26769139
Am J Clin Pathol. 2019 Jul 5;152(2):169-176
pubmed: 30984969
Dev Biol. 2002 Jul 1;247(1):11-25
pubmed: 12074549
Nat Immunol. 2010 Oct;11(10):889-96
pubmed: 20856220
Cancer Epidemiol Biomarkers Prev. 1998 Aug;7(8):689-96
pubmed: 9718221
Clin Breast Cancer. 2019 Oct;19(5):e617-e623
pubmed: 31101455
Cancers (Basel). 2020 Mar 06;12(3):
pubmed: 32155777
Histopathology. 2017 Aug;71(2):258-268
pubmed: 28326600
Cell Immunol. 2011;266(2):180-6
pubmed: 21040907